Abstract: A parking enforcement device can be secured to a surface adjacent to the area designated as NO PARKING. The enforcement device can include an elongated hollow body, a window provided to the tubular body, a battery, an internal frame assembly disposed inside of the elongated hollow body, and a camera disposed inside of the elongated hollow body. The internal frame assembly defines a cavity in which the battery is located. A camera support pole extends vertically upwards from the internal frame assembly. The camera is secured to the camera support pole and located vertically along the camera support pole such that the camera views outward through the window. A solar panel can be provided atop the parking enforcement device to recharge the battery.

Abstract: Provided are methods of treating a disease with arginine vasopressin or an analogue thereof that reduce the risk of hyponatremia. Specifically, the invention relates to the novel observation that subjects receiving co-administration of terlipressin and gabapentin or pregabalin have a high incidence of severe hyponatremia.

Abstract: The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a method for treating or alleviating endometriosis or adenomyosis uteri, involves administering an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

Abstract: The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

Abstract: The present invention provides novel methods of preventing or treating peripheral neuropathies, and of preventing or treating pain symptoms associated with diseases having peripheral neuropathies or astrocytic damages, and provides an agent for preventing or treating peripheral neuropathies or pain symptoms associated with diseases having peripheral neuropathies or astrocytic damages, which agent contains an RGM inhibiting substance.

Abstract: The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively.

Abstract: The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively.

Abstract: The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(1-cyclopropy-lisoquinolm-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

Abstract: The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively.

Abstract: The present invention provides a pharmaceutical composition, and provides for the use thereof for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof. The pharmaceutical composition comprises a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms, and esters thereof, together with a pharmaceutical carrier, and provides a relatively low plasma concentration variation of paliperidone to the psychiatric patient in need of treatment. The present invention also provides for the use of a pharmaceutical composition as defined above, in the preparation of a medicament for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof.